Latest News and Press Releases

€8 million milestone payment triggered by pre-clinical progression in oral IL-17A inhibitor programme 27 May 2025 – C4X Discovery Holdings Ltd (“C4XD”), a pioneering Drug Discovery company, today...

C4X Discovery Holdings Limited PatientSeek identifies a genetic signature that separates a4b7 integrin therapy responder and non-responder populations in inflammatory bowel disease Progresses...

C4X Discovery Holdings Limited C4XD announces progress on immuno-inflammation programmes and appointment of new Board members 22 July 2024 - C4X Discovery Limited (“C4XD”), a pioneering drug...

This announcement contains inside information C4X Discovery Holdings plc("C4XD", "C4X Discovery" or the "Company") Half-year results for the six months ended 31 January 2023 Up to $402 million...

First validation of C4XD's patient sub-groups through a Garvan-led retrospective clinical trial analysis Promising initial result paves way for novel approaches in Parkinson's disease...

C4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and commercial milestones, and tiered mid-single digit royalties Agreement further substantiates C4XD's...

C4X Discovery Holdings plc C4X Discovery receives first milestone payment from Sanofi €3 million milestone payment triggered by pre-clinical progression in oral IL-17A inhibitor programme ...

C4X Discovery Holdings plc Up to €414 million Exclusive Worldwide Licensing Agreement with Sanofi for C4XD oral IL-17A inhibitor programme €7 million upfront payment in addition to potential...

C4X Discovery Holdings plc Up to €414 million Exclusive Worldwide Licensing Agreement with Sanofi for C4XD oral IL-17A inhibitor programme €7 million upfront payment in addition to potential...

C4X Discovery Holdings plc (“C4XD”, “C4X Discovery” or the “Company”) C4X Discovery and PhoreMost collaboration to accelerate Parkinson’s Disease drug discovery pipeline 25 June 2019 – C4X...